Azzad Asset Management Inc. ADV Trims Stake in Illumina, Inc. (NASDAQ:ILMN)

Azzad Asset Management Inc. ADV lessened its position in Illumina, Inc. (NASDAQ:ILMN) by 2.8% in the first quarter, HoldingsChannel reports. The firm owned 3,857 shares of the life sciences company’s stock after selling 112 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Illumina were worth $530,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ILMN. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after buying an additional 125 shares in the last quarter. VisionPoint Advisory Group LLC boosted its stake in Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in Illumina in the fourth quarter worth about $37,000. Massmutual Trust Co. FSB ADV increased its stake in shares of Illumina by 86.8% during the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after purchasing an additional 132 shares in the last quarter. Finally, Gradient Investments LLC lifted its holdings in shares of Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

NASDAQ:ILMN traded down $0.13 on Wednesday, reaching $105.38. 452,455 shares of the company’s stock traded hands, compared to its average volume of 2,182,589. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. The stock has a 50-day simple moving average of $110.95 and a 200-day simple moving average of $126.99. The firm has a market cap of $16.79 billion, a PE ratio of -13.06 and a beta of 1.15. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $195.64.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business’s quarterly revenue was down 1.0% on a year-over-year basis. During the same period last year, the firm earned $0.08 earnings per share. Equities research analysts forecast that Illumina, Inc. will post 0.98 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. StockNews.com assumed coverage on Illumina in a research note on Sunday. They issued a “buy” rating on the stock. Royal Bank of Canada reduced their price target on shares of Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a research report on Monday. Barclays lifted their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Finally, TD Cowen reduced their price target on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $157.62.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.